Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial

Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs

John Concato, Nirav R. Shah, Ralph I. Horwitz · New England Journal of Medicine · 2000 · 3.5K citations · Full text

Public Health, Clinical Sciences, Clinical Epidemiology +11

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

Salim Yusuf, Marc A. Pfeffer, Karl Swedberg et al. · The Lancet · 2003 · 3K citations

Medicine, Cardiology, Internal Medicine +12

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

John J.V. McMurray, Jan Östergren, Karl Swedberg et al. · The Lancet · 2003 · 2.6K citations

Medicine, Cardiology, Pharmacology +15

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)

Karl Swedberg, John G.F. Cleland, Henry Dargie et al. · European Heart Journal · 2005 · 2.3K citations · Full text

Medicine, Cardiology, Internal Medicine +17

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

Marc A. Pfeffer, Karl Swedberg, Christopher B. Granger et al. · The Lancet · 2003 · 1.9K citations

Pharmacy, Cardiology, Pharmacotherapy +11